Biophage Pharma CEO to Present at BioContact 2004.MONTREAL -- Dr Mandeville Will Provide Corporate Update to Prospective Investors and Partner Companies Biophage Pharma Inc. (TSX-V: BUG), a biopharmaceutical company engaged in the development of new therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. and clinical diagnostics based on its leading expertise in immunology immunology, branch of medicine that studies the response of organisms to foreign substances, e.g., viruses, bacteria, and bacterial toxins (see immunity). Immunologists study the tissues and organs of the immune system (bone marrow, spleen, tonsils, thymus, lymphatic and phage therapy Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections. Bacteriophages, or "phages" are viruses that invade only bacterial cells and, in the case of lytic , today announced that President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Rosemonde Mandeville will present an updated corporate profile at the upcoming 2004 BioContact in Quebec City. "I am very excited about the opportunity to present an overview of Biophage at such a high profile event. Since taking over as CEO position at Biophage, we have rationalized our approach and focused our efforts on the detection and management of bacterial bacterial /bac·te·ri·al/ (-al) pertaining to or caused by bacteria. bacterial pertaining to or caused by bacteria. bacterial adhesiveness see adhesins. infections. We made significant progress in the development of our nanosensors as well as a number of other areas," stated Dr. Rosemonde Mandeville, President and Chief Executive Officer of Biophage Pharma. "With our recent financing we are now able to pursue the development of our phage-based platforms and develop new opportunities and applications of our technologies. I am looking forward to presenting a more complete picture of Biophage at this event, " added Dr. Mandeville. About Biophage Pharma Inc. Biophage Pharma Inc. is a Canadian biopharmaceutical company developing new therapeutic and diagnostic products using phage-based technology. Founded in 1995, Biophage is located at the Biotechnology Research Institute in Montreal and employs 15 people, including a team of 13 researchers. Through an active research and development program, as well as in-licensing and collaboration agreements, Biophage is building a portfolio of promising new therapeutics collaboration agreements, Biophage is building a portfolio of promising new therapeutics (www.biophage.com). Biophage Pharma Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:BUG) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion